Welcome to our dedicated page for HCA Healthcare SEC filings (Ticker: HCA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
HCA Healthcare filings document a NYSE-listed healthcare services company whose common stock is registered under Section 12(b) and whose wholly owned subsidiary, HCA Inc., issues senior unsecured notes guaranteed by the parent. Recent 8-K reports record quarterly operating results, dividends, share repurchase authorization, commercial paper and debt refinancing activity, and indenture supplements for senior notes.
Proxy and annual-meeting disclosures cover director elections, shareholder voting results, board matters, executive compensation, and performance award programs linked to EBITDA and quality measures. Registration and offering-related filings describe shelf registration use, prospectus supplements, note terms, guarantees, trustee arrangements and capital-structure disclosures for HCA's healthcare services operations.
HCA Healthcare SVP & Chief Nurse Executive Erica Rossitto reported equity compensation activity. On February 10, 2026, she acquired 1,676 shares of HCA common stock at $0 per share from the vesting of performance share units. On the same date, 418 shares at $502.05 per share were withheld and disposed of to cover tax obligations, leaving her with 10,407 directly held shares.
The vested shares arose from an original grant of 838 performance share units made on January 30, 2023. These units could vest between 0% and 200% based on cumulative earnings per share performance for fiscal years 2023–2025, and the company’s results led to vesting at 200% of the units granted.
HCA Healthcare executive Michael R. McAlevey reported equity compensation activity in company common stock. On February 10, 2026, he acquired 8,372 shares at $0 per share as a grant tied to previously awarded performance share units. On the same date, 3,006 shares were withheld at $502.05 per share to satisfy tax obligations, leaving him with 8,853 directly owned shares. The filing also shows 2,111 shares held indirectly through a 2024 GRAT and 26 shares in a fully managed account over which he has no investment authority and for which he disclaims beneficial ownership beyond any pecuniary interest.
HCA Healthcare EVP and CFO Mike A. Marks reported equity compensation activity involving HCA common stock. On February 10, 2026, he acquired 5,026 shares at $0 per share in a grant classified as an award.
On the same date, 1,690 shares of common stock were disposed of at $502.05 per share to satisfy tax obligations through share withholding, leaving 3,336 directly owned shares. The filing also shows 43,240 shares held indirectly by the MAM 2020 Trust and 26,500 shares held indirectly by the LAM 2020 Trust.
A footnote explains this grant stems from 2,513 performance share units awarded on January 30, 2023, which could vest from zero to double the units based on 2023-2025 cumulative earnings per share. Based on company performance, 200% of the units vested.
HCA Healthcare CEO Samuel N. Hazen reported equity transactions in company common stock. On February 10, 2026, he acquired 54,934 shares at $0 per share as a grant tied to performance share units that fully vested at 200% of the original award.
On the same date, 21,323 shares were disposed of at $502.05 per share to satisfy tax withholding obligations, leaving 64,842 shares held directly. He also reports indirect ownership, including 200,000 shares held by a 2025 GRAT and 813,320 shares held by an LP.
HCA Healthcare EVP and COO Jon M. Foster reported equity award activity. On February 10, 2026, he acquired 15,696 shares of common stock at $0 per share as a grant. On the same date, 5,888 shares were withheld at $502.05 per share to cover tax obligations, leaving 23,062 directly held shares.
The award relates to 7,848 performance share units granted on January 30, 2023, which could vest from zero to twice the original grant based on cumulative earnings per share for fiscal years 2023–2025. Based on the company’s earnings performance, 200% of the units vested, resulting in the reported share delivery.
HCA Healthcare EVP and Chief Clinical Officer Michael S. Cuffe reported equity award activity in company stock. On February 10, 2026, he acquired 9,628 shares of common stock at $0 per share through a grant or award, increasing his direct holdings to 35,580.9017 shares.
On the same date, 3,501 shares were disposed of at $502.05 per share to satisfy tax withholding obligations, leaving him with 32,079.9017 directly owned shares. These shares relate to 4,814 performance share units granted on January 30, 2023 that vested at 200% of the original grant based on 2023–2025 earnings per share performance.
HCA Healthcare SVP & Chief Human Resources Officer Jennifer Berres reported multiple stock transactions. On February 10, 2026, she acquired 7,116 shares of common stock at $0 from previously granted performance share units that vested at 200% of the original 3,558-unit award after HCA met its 2023–2025 earnings per share goals. The same day, 2,515 shares were withheld at $502.05 per share to cover tax obligations. On February 11, 2026, she sold 4,010 shares at $503 per share and another 4,010 shares at a weighted average price of $526.1646, leaving her with 11,993 directly owned shares.
A shareholder of HCA Healthcare, Inc. filed a Rule 144 notice to sell 8,020 shares of common stock, with an aggregate market value of 4,126,949.9. The planned sale is through Merrill Lynch on the NYSE, with an approximate sale date of 02/11/2026.
The shares to be sold were acquired via vesting of stock awards from HCA Healthcare, Inc. on 02/17/2023 (5,159 shares), 02/16/2024 (1,680 shares), and 02/13/2025 (1,181 shares), each described as a compensatory payment. The notice also states that the seller represents they do not know any undisclosed material adverse information about HCA’s operations.
HCA Healthcare insider Thomas F. Frist Jr. reported an internal reorganization of his indirect holdings. On February 6, 2026, Frisco Holding II exchanged 36,629,188 existing HCA shares for 36,557,141 newly issued shares from HCA in a transaction exempt under Rule 16b-3 and treated as a tax reorganization.
After the exchange, Frisco Holding II holds 36,557,141 HCA shares, and Hercules Holding II holds 32,282,889 shares. Frist may be deemed to have voting and investment control over these entities but disclaims beneficial ownership except for his pecuniary interests, which are tied to specified partnership units and trusts.
HCA Healthcare director and 10% owner William R. Frist reported complex internal equity moves involving investment entities tied to his family. On February 6, 2026, Frisco Holding II exchanged 36,629,188 existing HCA shares for 36,557,141 newly issued shares from HCA in a tax-related reorganization treated as a partnership conversion and Section 368(a) reorganization.
After the transactions, Frisco Holding II holds 36,557,141 HCA shares and Hercules Holding II holds 32,282,889 shares, with additional indirect holdings through trusts, family partnerships, and family members. Frist may be deemed to have voting and investment control over these entities but formally disclaims beneficial ownership beyond his economic interests. His direct holding of 12,931 shares includes restricted share units payable in 12,875 shares when he leaves the board.